Mdxhealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that the Company received an additional notification letter (the "Additional Letter") from The Nasdaq Stock Market LLC ("Nasdaq") related to the recent reduction in the price for the Company’s ordinary shares. The initial notice, reported by the Company in its Form 6-K filed on July 2, 2026, related to the Company’s non-compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing. The Supplemental Letter, received on July 20, 2026, notifies the Company that it is not in compliance with the minimum market value requirement set forth in rules for continued listing on The Nasdaq Capital Market.